Menon R - Search Results

1

Relationship Between Venetoclax Exposure and Undetectable Minimal Residual Disease Rates in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of Six Clinical Studies.

Gopalakrishnan S, Menon R, Suleiman AA, Kater AP, Stilgenbauer S, Seymour JF, Chyla B, Lu T, Young Kim S, Roberts AW, Woyach JA, Mensing S, Salem AH. Gopalakrishnan S, et al. Among authors: menon r. Hemasphere. 2023 Nov 17;7(12):e983. doi: 10.1097/HS9.0000000000000983. eCollection 2023 Dec. Hemasphere. 2023. PMID: 38026788 Free PMC article. No abstract available.

2

Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 Studies.

Mensing S, Polepally AR, König D, Khatri A, Liu W, Podsadecki TJ, Awni WM, Menon RM, Dutta S. Mensing S, et al. Among authors: menon rm. AAPS J. 2016 Jan;18(1):270-80. doi: 10.1208/s12248-015-9846-1. Epub 2015 Nov 23. AAPS J. 2016. PMID: 26597291 Free PMC article.

3

Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies.

Polepally AR, Mensing S, Khatri A, Beck D, Liu W, Awni WM, Menon RM, Dutta S. Polepally AR, et al. Among authors: menon rm. Clin Pharmacokinet. 2016 Sep;55(9):1091-101. doi: 10.1007/s40262-016-0385-4. Clin Pharmacokinet. 2016. PMID: 27000758 Clinical Trial.

4

Exposure-Response Relationship for Ombitasvir and Paritaprevir/Ritonavir in Hepatitis C Virus Subgenotype 1b-Infected Japanese Patients in the Phase 3 Randomized GIFT-I Study.

Gopalakrishnan S, Khatri A, Mensing S, Redman R, Menon R, Zha J. Gopalakrishnan S, et al. Among authors: menon r. Adv Ther. 2016 Apr;33(4):670-83. doi: 10.1007/s12325-016-0320-y. Epub 2016 Mar 21. Adv Ther. 2016. PMID: 27084721 Clinical Trial.

5

Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients.

Khatri A, Mensing S, Podsadecki T, Awni W, Menon R, Dutta S. Khatri A, et al. Among authors: menon r. Clin Drug Investig. 2016 Aug;36(8):625-35. doi: 10.1007/s40261-016-0407-x. Clin Drug Investig. 2016. PMID: 27153823 Clinical Trial.

6

Effects of Mild and Moderate Renal Impairment on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, and Ribavirin Pharmacokinetics in Patients with Chronic HCV Infection.

Polepally AR, Badri PS, Eckert D, Mensing S, Menon RM. Polepally AR, et al. Among authors: menon rm. Eur J Drug Metab Pharmacokinet. 2017 Apr;42(2):333-339. doi: 10.1007/s13318-016-0341-6. Eur J Drug Metab Pharmacokinet. 2017. PMID: 27165046

7

Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection.

Gopalakrishnan SM, Polepally AR, Mensing S, Khatri A, Menon RM. Gopalakrishnan SM, et al. Among authors: menon rm. Clin Pharmacokinet. 2017 Jan;56(1):1-10. doi: 10.1007/s40262-016-0423-2. Clin Pharmacokinet. 2017. PMID: 27314261 Clinical Trial.

8

Effect of co-medications on paritaprevir, ritonavir, ombitasvir, dasabuvir and ribavirin pharmacokinetics: analysis of data from seven Phase II/III trials.

Polepally AR, Badri PS, Parikh A, Rodrigues L Jr, Da Silva-Tillmann BA, Mensing S, Podsadecki TJ, Awni WM, Dutta S, Menon RM. Polepally AR, et al. Among authors: menon rm. Antivir Ther. 2016;21(8):707-714. doi: 10.3851/IMP3079. Epub 2016 Sep 1. Antivir Ther. 2016. PMID: 27584548

9

Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials.

Mensing S, Eckert D, Sharma S, Polepally AR, Khatri A, Podsadecki TJ, Awni WM, Menon RM, Dutta S. Mensing S, et al. Among authors: menon rm. Br J Clin Pharmacol. 2017 Mar;83(3):527-539. doi: 10.1111/bcp.13138. Epub 2016 Nov 3. Br J Clin Pharmacol. 2017. PMID: 27662429 Free PMC article.

10

Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.

Freise KJ, Jones AK, Menon RM, Verdugo ME, Humerickhouse RA, Awni WM, Salem AH. Freise KJ, et al. Hematol Oncol. 2017 Dec;35(4):679-684. doi: 10.1002/hon.2373. Epub 2016 Dec 16. Hematol Oncol. 2017. PMID: 27982454

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,836 results

Search Page

Filters